GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Metastatic Prostate Cancer overview

Metastatic prostate cancer occurs when cancerous cells from the prostate gland spread via the bloodstream or lymphatic system to distant sites, especially the bones (such as the spine, pelvis, or hips), lymph nodes, liver, lungs, and other organs. It’s considered an advanced stage of prostate cancer and can present challenges in treatment and management. Metastatic prostate cancer can cause various symptoms depending on the organs affected, including bone pain (often in the spine, hips, or ribs), urinary problems, erectile dysfunction, weakness or numbness in the legs or feet, weight loss, and fatigue.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.

Data Insights Likelihood of Approval Analysis for Metastatic Prostate Cancer